Not for publication, distribution or release, directly or indirectly, in whole or in part, within or into the United Kingdom, US, Canada, Japan, Australia, Hong Kong, New Zealand or any other jurisdiction in which such publication, distribution or release may be contravening to any applicable laws or rules. Additional restrictions are applicable, please see “Important information” in the end of this press release.
Timetable for the Rights Issue
Record date for participation in the Rights Issue
May 25, 2021
May 27 – June 10, 2021
Trading in subscription rights
May 27 – June 7, 2021
Trading in BTAs
May 27 – June 14, 2021
Announcement of final outcome in the Rights Issue
Around June 14, 2021
Delivery of and trading in new shares subscribed with subscription rights
Around June 18, 2021
Delivery of and trading in new shares subscribed without subscription rights
Around June 30, 2021
For full information regarding the Rights Issue, please refer to the prospectus, which is available on Isofol’s website, www.isofolmedical.com. Link to the application form is available on the same link at the start of the subscription period at the latest, and on Carnegie Investment Bank AB (publ)’s website, www.carnegie.se. The prospectus is also available on the Swedish Financial Supervisory Authority’s (Sw. Finansinspektionen) website, www.fi.se.
Carnegie Investment Bank AB (publ) and Pareto Securities AB act as Joint Bookrunners in connection with the Rights Issue. Vinge law firm acts as legal adviser to Isofol, and Schjødt law firm acts as legal adviser to the Joint Bookrunners. Ashurst LLP acts as legal adviser to the Joint Bookrunners as to US securities law.
For further information, please contact
Isofol Medical AB (publ)
Jarl Ulf Jungnelius, M.D., Chief Executive Officer
Mobil: +46 (0) 709 16 89 55
FNCA Sweden AB
Phone: +46 (0)8 528 003 99